Changes in Beneficial Ownership · 4
Arcutis Biotherapeutics, Inc.
ARQTNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1786666006.xml
Filing details
- Report period
- 2026-08-11
- Issuer
- Arcutis Biotherapeutics, Inc.
- Issuer CIK
- 0001787306
- Trading symbol
- ARQT
Reporting owner 1
- Name
- Burnett Patrick
- Reporting owner CIK
- 0001741987
- Relationship
- Officer
- Officer title
- See Remarks
- Address
- C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE, CA, 91361
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-11 | M · Form 4[F1] | 8,300 | A | 3.64 | 127,589 | D |
| Common Stock | 2026-08-11 | S · Form 4[F1] | 8,300 | D | 26.5216[F2] | 119,289 | D |
| Common Stock | 2026-08-12 | M · Form 4[F1] | 6,700 | A | 3.64 | 125,989 | D |
| Common Stock | 2026-08-12 | S · Form 4[F1] | 6,700 | D | 26.0847[F3] | 119,289 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 3.64 | 2026-08-11 | M · Form 4[F1] | 8,300 | D | 0 | [F1] | 2034-01-12 | Common Stock | 8,300 | 135,450 | D |
| Stock Option (right to buy) | 3.64 | 2026-08-12 | M · Form 4[F1] | 6,700 | D | 0 | [F1] | 2034-01-12 | Common Stock | 6,700 | 128,750 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8
- F2
- The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.50 to $26.57, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.↩ 1
- F3
- The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.19, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.↩ 1
Remarks
Reporting Person's title: EVP, Chief Medical Officer
Signature 1
- Signed
- /s/ Latha Vairavan, as Attorney-in-Fact for Patrick Burnett
- Date
- 2026-08-13